On Aug. 17, 2022, Turning Point Therapeutics became a wholly owned subsidiary of Bristol Myers Squibb

Responsible for deal sourcing, due diligence and transaction execution to in-license innovative products in oncology, immunology and infectious disease therapeutic areas. Alliance Manager to US partner companies.

Due Diligence Lead responsible for managing the team of senior experts in evaluation of business development and M&A opportunities in close liaison with R&D and Business Unit sponsors o Identification, coordination of high quality cross-functional due diligence teams to conduct evaluation, independent of the sponsor, to ensure the best Investment decisions for external opportunities o Setting clear goals and timelines, solve problems and propose solutions in complex situationso Identification of external experts and conducting KOL interviews in support of evaluationo Development of investment recommendation and influence of internal decision makers on interest/value of progressing to negotiation after due diligenceo Effective communication across organization including but not limited to R&D and GBU teams and senior managemento Providing support to internal governance/committees

Clinical/Medical lead responsible for development and execution of clinical trials o Protocol development (pain management, rheumatology, gynecologic and colorectal surgery trial protocols developed), medical monitoring, pre-IDE and IDE submissionsClinical development input into Medical Affairs studies Clinical development representative on pre-clinical and translational medicine R&D projects o CDP development, FIM/PoC study design, regulatory submission in close collaboration with Regulatory Affairs teamo FDA presentationsRegulatory Affairs support o Clinical evaluation reports for PMA, BSI submissionsDiligence and competitive analysis of relevant internal and external candidates for clinical developmento Build and strengthen relationships with external stakeholders including KOLs and consultants (e.g. organize and conduct advisory boards)o Inform and influence internal decision making on clinical and business development projects

Discovery project lead evaluating the role of a novel target in osteoarthritis-induced pain; critical in identifying lead candidate series and moving the project forward into the next stage of development  Osteoarthritis pain program lead, supporting assay/animal model development and new technology/methodology evaluation (behavioral, molecular, imaging) Authoring scientific manuscripts and research protocols Team lead Osteoarthritis research core team meeting  Novel target for OA pain working group

 Established previously non-existing pain program within Orthopedic Research Portfolio  Brought on board an array of behavioral and molecular pain metrics, leveraged expertise in immunohistochemistry, ensuring a fully functional pain program (vivo and in vitro) which has contributed significantly to the success of the portfolio Maximized skills of research associates in a variety of behavioral tests for measuring pain in animals Successfully presented a number of lectures that improved knowledge of peers, subordinates and senior management on pain, mechanisms of pain signaling, as well as currently available treatments and novel approaches in development Facilitated discussions on different targets of interest for the treatment of osteoarthritis pain and lead research efforts that defined the most appropriate targets